NVRO241220C35000
- 0.30
- 0.000.00%
Nevro Newsroom
RBC Capital Remains a Hold on Nevro Corp (NVRO)
Truist Financial Maintains Nevro(NVRO.US) With Hold Rating, Cuts Target Price to $4.7
Pain Management Devices Global Analysis Report 2024-2034 Featuring Abbott Laboratories, Boston Scientific, Medtronic, Nevro, Baxter, OMRON, Stryker, Teleflex, ICU Medical, AtriCure, and Zynex
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Mizuho Securities Maintains Nevro(NVRO.US) With Hold Rating, Announces Target Price $6
Here's Why You Should Retain Nevro Stock in Your Portfolio Now
Nevro Is Maintained at Neutral by Citigroup
Nevro Is Maintained at Equal-Weight by Wells Fargo
Citi Maintains Nevro(NVRO.US) With Hold Rating, Cuts Target Price to $5
Express News | Nevro Corp : Citigroup Cuts Target Price to $5 From $6
Zacks.com Featured Highlights Include Stryve Foods, Nevro, Canoo, MSA Safety and VTEX
Canaccord Genuity Maintains Hold on Nevro, Lowers Price Target to $4
Wells Fargo Upgrades Nevro(NVRO.US) to Hold Rating, Cuts Target Price to $5
Wells Fargo Reinstates Equal-Weight on Nevro, Announces $5 Price Target
Nevro Corp: Hold Rating Amid Market Challenges and Strategic Uncertainty
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Nevro Cut to Underweight From Equal-Weight by Morgan Stanley
Nevro Analyst Ratings
Morgan Stanley Downgrades Nevro(NVRO.US) to Sell Rating, Cuts Target Price to $4